Center for Biosimilars

Biosimilar Denosumab Could Reshape Access, Costs in Osteoporosis Care: Edward Li, PharmD

Sandoz's Edward Li explains how biosimilar denosumab pricing could reshape cost-effectiveness, payer access, and gaps in ...
Center for Biosimilars

Step Therapy to Biosimilars, Branded Anti-VEGF Costs More, Data Show

Patients with neovascular age-related macular degeneration (nAMD) who transitioned from off-label bevacizumab to a biosimilar and then to a branded anti-VEGF agent had longer injection intervals ...
Center for Biosimilars

Natalizumab Biosimilar Shows Limited Cost-Effectiveness in MS

A study found no direct trial evidence for natalizumab or its biosimilar in MS and found limited cost-effectiveness vs most ...
Center for Biosimilars

Nonmedical Adalimumab Biosimilar Switch Maintains Disease Control in Pediatric IBD

Most pediatric and young adult patients with IBD maintained stable disease activity and laboratory markers after switching ...
centerforbiosimilars

James D. Chambers, PhD, MPharm, MSc

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Paul Cornes, BM, BCH, MA, MRCP, FRCR

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Cyrus Karkaria, PhD

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Basit Chaudhry, MD, PhD

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Chelsee Jensen, PharmD

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Alex Keeton

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Tyler Sandahl, PharmD

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Ayaaz Hussain Khan, PhD

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...